Amgen AMG 757 (Small Cell Lung Cancer)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Receive the study drug (tarlatamab) intravenously
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
What is the Condition Being Studied?
Small Cell Lung Cancer (SCLC)

Who Can Participate in this Study?

Adults who:

- Are diagnosed with SCLC

- Did not respond to previous treatment or had their cancer return after treatment ended

For more information about who can join this study, please contact the study team at 919-681-6468.

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if an experimental drug called tarlatamab is a safe and effective treatment for SCLC.

Study Details

Full Title
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of
Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Principal Investigator

Protocol Number

View on